Align Technology (NASDAQ:ALGN – Get Free Report) and Nexalin Technology (NASDAQ:NXL – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.
Risk & Volatility
Align Technology has a beta of 1.74, meaning that its stock price is 74% more volatile than the S&P 500. Comparatively, Nexalin Technology has a beta of 4.31, meaning that its stock price is 331% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for Align Technology and Nexalin Technology, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Align Technology | 1 | 7 | 8 | 1 | 2.53 |
| Nexalin Technology | 1 | 1 | 0 | 0 | 1.50 |
Align Technology presently has a consensus target price of $193.08, indicating a potential upside of 15.64%. Given Align Technology’s stronger consensus rating and higher probable upside, equities analysts clearly believe Align Technology is more favorable than Nexalin Technology.
Earnings and Valuation
This table compares Align Technology and Nexalin Technology”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Align Technology | $4.03 billion | 2.92 | $410.35 million | $6.87 | 24.30 |
| Nexalin Technology | $300,000.00 | 3.63 | -$8.22 million | ($14.41) | -0.10 |
Align Technology has higher revenue and earnings than Nexalin Technology. Nexalin Technology is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
88.4% of Align Technology shares are held by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are held by institutional investors. 0.7% of Align Technology shares are held by insiders. Comparatively, 16.9% of Nexalin Technology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Align Technology and Nexalin Technology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Align Technology | 11.83% | 15.96% | 10.48% |
| Nexalin Technology | -4,141.94% | -278.24% | -218.42% |
Summary
Align Technology beats Nexalin Technology on 12 of the 15 factors compared between the two stocks.
About Align Technology
Align Technology, Inc. develops, manufactures and markets digital orthodontic and restorative dentistry products. Its best-known offering is the Invisalign system, which uses a series of custom-made clear aligners to straighten teeth. The company also sells Vivera retainers and iTero intraoral scanners, which support digital dental imaging and treatment planning. Founded in 1997, Align helped popularize clear-aligner orthodontic treatment as an alternative to traditional braces. Its digital dentistry portfolio also includes exocad software, used by dental professionals and laboratories to design dental restorations.
About Nexalin Technology
Nexalin Technology, Inc. (NASDAQ:NXL) is a medical technology company focused on developing and commercializing noninvasive neurostimulation devices for mental health and neurological applications. Its technology is designed to deliver low-intensity electrical stimulation to the brain with the goal of influencing neural activity associated with conditions such as depression, anxiety, insomnia, post-traumatic stress disorder and substance-use disorders. The company’s product portfolio includes the Gen-2 and Gen-3 neurostimulation systems.
Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.
